Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019)
Forte Biosciences (FBRX) reported EBITDA Margin of 117955.56% for Q4 2019, up 9985556.0% year-over-year from N/an in Q4 2018, and up 43.38% quarter-over-quarter from 208311.11% in Q3 2019.
Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has 3 years of EBITDA Margin data on file, last reported at 117955.56% in Q4 2019.
- EBITDA Margin for Q4 2019 came in at 117955.56%, up 9985556.0% year-over-year; the trailing twelve-month figure through Dec 2019 was 176341.67% (down 17607030.0% YoY), and the FY2019 annual result was 176341.67%, down 17607030.0% from the prior year.
- EBITDA Margin advanced to 117955.56% in Q4 2019 per FBRX's latest filing, from 208311.11% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1.95% in Q3 2018 and troughed at 217811.11% in Q4 2018.
- A 3-year average of 140379.07% and a median of 143933.33% in 2018 frame the typical range for EBITDA Margin.
- On a YoY basis, EBITDA Margin climbed as much as 9985556 bps in 2019 and fell as far as 20830916 bps in 2019.
- A 3-year view of EBITDA Margin shows it stood at 108680.0% in 2017, then sank by 100 bps to 217811.11% in 2018, then surged by 46 bps to 117955.56% in 2019.
- Business Quant data shows FBRX's EBITDA Margin at 117955.56% in Q4 2019, 208311.11% in Q3 2019, and 189733.33% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -117,955.56% |
| Sep 30, 2019 | -208,311.11% |
| Jun 30, 2019 | -189,733.33% |
| Mar 31, 2019 | -189,366.67% |
| Dec 31, 2018 | -217,811.11% |
| Sep 30, 2018 | -1.95% |
| Jun 30, 2018 | -178,166.67% |
| Mar 31, 2018 | -143,933.33% |
| Dec 31, 2017 | -108,680.00% |
| Sep 30, 2017 | -99,490.00% |
| Jun 30, 2017 | -90,720.00% |